EEG biomarker informed prescription of antidepressants in MDD: a feasibility trial.

Journal Article (Journal Article)

Using pre-treatment biomarkers to guide patients to the preferred antidepressant medication treatment could be a promising approach to enhance its current modest response and remission rates. This open-label prospective study assessed the feasibility of using such pre-treatment biomarkers, by using previously identified EEG features (paroxysmal activity; alpha peak frequency; frontal alpha asymmetry) to inform the clinician in selecting among three different antidepressants (ADs; escitalopram, sertraline, venlafaxine) as compared to Treatment As Usual (TAU). EEG data were obtained from 195 outpatients with major depressive disorder prior to eight weeks of AD treatment. Primary outcome measure was the percentage change between before and after treatment on the Beck Depression Inventory-II (BDI-II). We compared TAU and EEG-informed prescription through AN(C)OVAs. Recruitment started with patients receiving TAU to establish baseline effectiveness, after which we recruited patients receiving EEG-informed prescription. 108 patients received EEG-informed prescription and 87 patients received TAU. Clinicians and patients were satisfied with the protocol. Overall, 70 (65%) of the EEG-informed clinicians followed recommendations (compared to 52 (60%) following prescriptions in the TAU group), establishing feasibility. We here confirm that treatment allocation informed by EEG variables previously reported in correlational studies, was feasible.

Full Text

Duke Authors

Cited Authors

  • van der Vinne, N; Vollebregt, MA; Rush, AJ; Eebes, M; van Putten, MJAM; Arns, M

Published Date

  • March 2021

Published In

Volume / Issue

  • 44 /

Start / End Page

  • 14 - 22

PubMed ID

  • 33509659

Electronic International Standard Serial Number (EISSN)

  • 1873-7862

Digital Object Identifier (DOI)

  • 10.1016/j.euroneuro.2020.12.005

Language

  • eng

Conference Location

  • Netherlands